{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:04:21Z","timestamp":1790269461382,"version":"4.1.0"},"reference-count":163,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.ejmech.2017.02.011","type":"journal-article","created":{"date-parts":[[2017,2,9]],"date-time":"2017-02-09T16:32:19Z","timestamp":1486657939000},"page":"53-71","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Strategies in the designing of prodrugs, taking into account the antiviral and anticancer compounds"],"prefix":"10.1016","volume":"129","author":[{"given":"Monika A.","family":"Lesniewska-Kowiel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izabela","family":"Muszalska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2017.02.011_bib1","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1124\/pr.110.003459","article-title":"Prodrugs-from serendipity to rational design","volume":"63","author":"Huttunen","year":"2011","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejmech.2017.02.011_bib2","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/nrd2468","article-title":"Prodrugs: design and clinical applications","volume":"7","author":"Rautio","year":"2008","journal-title":"Nature Rev. Drug. Discov."},{"key":"10.1016\/j.ejmech.2017.02.011_bib3","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1021\/jm0303812","article-title":"Lessons learned from marketed and investigational prodrugs","volume":"47","author":"Ettmayer","year":"2004","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2017.02.011_bib4","article-title":"The prodrug approach: a successful tool for improving drug solubility","volume":"21","author":"Jornada","year":"2016","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2017.02.011_bib5","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/182421a0","article-title":"Chemical aspects of selective toxicity","volume":"182","author":"Albert","year":"1958","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2017.02.011_bib6","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1016\/j.bcp.2004.07.005","article-title":"Prodrug research: futile or fertile?","volume":"68","author":"Testa","year":"2004","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2017.02.011_bib7","series-title":"Prodrugs: Challenges and Rewards, Part 1 & 2","author":"Stella","year":"2007"},{"key":"10.1016\/j.ejmech.2017.02.011_bib8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S1734-1140(13)70959-9","article-title":"Prodrugs: a challenge for the drug development","volume":"65","author":"Zawilska","year":"2013","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.ejmech.2017.02.011_bib9","doi-asserted-by":"publisher","first-page":"4755","DOI":"10.1002\/jps.22205","article-title":"Prodrugs: some thoughts and current issues","volume":"99","author":"Stella","year":"2010","journal-title":"J.\u00a0Pharm. Sci."},{"key":"10.1016\/j.ejmech.2017.02.011_bib10","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.cbpa.2009.04.620","article-title":"Prodrugs: bridging pharmacodynamic\/pharmacokinetic gaps","volume":"13","author":"Testa","year":"2009","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.ejmech.2017.02.011_bib11","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1111\/cbdd.12224","article-title":"Prodrugs design based on inter- and intramolecular chemical processes","volume":"82","author":"Karaman","year":"2013","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ejmech.2017.02.011_bib12","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s13318-011-0035-z","article-title":"The rationality for using prodrug approach in drug discovery programs for new xenobiotics: opportunities and challenges","volume":"36","author":"Srinivas","year":"2011","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.ejmech.2017.02.011_bib13","series-title":"The Organic Chemistry of Drug Design and Drug Action","author":"Silverman","year":"2004"},{"key":"10.1016\/j.ejmech.2017.02.011_bib14","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.ejps.2010.09.014","article-title":"Codrug: an efficient approach for drug optimization","volume":"41","author":"Das","year":"2010","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejmech.2017.02.011_bib15","first-page":"599","article-title":"Prodrugs and soft drugs","volume":"58","author":"Sta\u0144czak","year":"2006","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.ejmech.2017.02.011_bib16","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.2174\/138955710793564179","article-title":"Bioprecursor prodrugs: molecular modification of the active principle","volume":"10","author":"Kokil","year":"2010","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.ejmech.2017.02.011_bib17","series-title":"Drug Design: Fact or Fantasy","first-page":"47","article-title":"Designing prodrugs and bioprecursors","author":"Wermuth","year":"1984"},{"key":"10.1016\/j.ejmech.2017.02.011_bib18","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1002\/jps.20542","article-title":"Enzymes involved in the bioconversion of ester-based prodrugs","volume":"95","author":"Liederer","year":"2006","journal-title":"J.\u00a0Pharm. Sci."},{"key":"10.1016\/j.ejmech.2017.02.011_bib19","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.drudis.2013.08.014","article-title":"Chemistry-enabled drug delivery (prodrugs): recent progress and challenges","volume":"19","author":"Clas","year":"2014","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2017.02.011_bib20","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1021\/tx015508+","article-title":"Synthesis of new carboxylesterase inhibitors and evaluation of potency and water solubility","volume":"14","author":"Wheelock","year":"2001","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.ejmech.2017.02.011_bib21","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S1074-5521(03)00071-1","article-title":"Crystal structure of human carboxylesterase 1 complexed with the Alzheimer's drug tacrine: from binding promiscuity to selective inhibition","volume":"10","author":"Benchairt","year":"2003","journal-title":"Chem. Biol."},{"key":"10.1016\/j.ejmech.2017.02.011_bib22","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.cbi.2006.07.001","article-title":"Structure, function and regulation of carboxylesterases","volume":"162","author":"Satoh","year":"2006","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.ejmech.2017.02.011_bib23","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1124\/dmd.30.5.488","article-title":"Current progress on esterases: from molecular structure to function","volume":"30","author":"Satoh","year":"2002","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejmech.2017.02.011_bib24","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S0959-8049(98)00058-6","article-title":"Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue","volume":"34","author":"Miwa","year":"1998","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejmech.2017.02.011_bib25","first-page":"1471","article-title":"The role of rat serum carboxylesterase in the activation of paclitaxel and camptothecin prodrugs","volume":"7","author":"Senter","year":"1996","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2017.02.011_bib26","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/(SICI)1520-636X(1999)11:1<10::AID-CHIR2>3.0.CO;2-E","article-title":"Characterization of esterases involved in the stereoselective hydrolysis of ester-type prodrugs of propranolol in rat liver and plasma","volume":"11","author":"Yoshigae","year":"1999","journal-title":"Chirality"},{"key":"10.1016\/j.ejmech.2017.02.011_bib27","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1021\/cr00081a005","article-title":"Acetylcholinesterse: enzyme structure, reaction dynamics, and virtual transition states","volume":"87","author":"Quinn","year":"1987","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2017.02.011_bib28","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1002\/jps.1101","article-title":"Transport of acyclovir ester prodrugs through rabbit cornea and SIRC-rabbit corneal epithelial cell line","volume":"90","author":"Tak","year":"2001","journal-title":"J.\u00a0Pharm. Sci."},{"key":"10.1016\/j.ejmech.2017.02.011_bib29","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1159\/000267220","article-title":"Characterization of esterases involved in the hydrolysis of dipivefrin hydrochloride","volume":"25","author":"Nakamura","year":"1993","journal-title":"Ophtalmic. Res."},{"key":"10.1016\/j.ejmech.2017.02.011_bib30","doi-asserted-by":"publisher","first-page":"5512","DOI":"10.1073\/pnas.0307659101","article-title":"Acetylcholinesterase\/paraoxonase genotype and expression predict anxiety scores in health, risk factors, exercise training, and genetics study","volume":"101","author":"Sklan","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2017.02.011_bib31","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.bbrc.2004.08.019","article-title":"Acetylcholine esterase protects LDL against oxidation","volume":"322","author":"Fuhrman","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2017.02.011_bib32","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1124\/mol.62.2.220","article-title":"Re-engineering butyrylcholinesterase as a cocaine hydrolase","volume":"62","author":"Sun","year":"2002","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2017.02.011_bib33","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/0163-7258(90)90044-3","article-title":"Genetic variants of human serum cholinesterase influence metabolism of the muscle relaxant succinylcholine","volume":"47","author":"Lockridge","year":"1990","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2017.02.011_bib34","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0167-4838(98)00104-6","article-title":"Butyrylcholineste-rase-catalysed hydrolysis of aspirin, a negatively charged ester, and aspirin related neutral esters","volume":"1387","author":"Masson","year":"1998","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejmech.2017.02.011_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-3565(25)32246-9","article-title":"Hydrolysis of diacetylmorphine (heroin) by human serum cholinesterase","volume":"215","author":"Lockridge","year":"1980","journal-title":"J.\u00a0Pharmac. Exp. Ther."},{"key":"10.1016\/j.ejmech.2017.02.011_bib36","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.1016\/0006-2952(88)90068-8","article-title":"Hydrolysis of 3H-bambuterol, a carbamate prodrug of terbutaline, in blood from humans and laboratory animals in\u00a0vitro","volume":"37","author":"Tunek","year":"1988","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2017.02.011_bib37","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0090-9556(25)07879-1","article-title":"Hydrolysis of methylprednisolone acetate by human serum cholinesterase","volume":"10","author":"Meyers","year":"1982","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejmech.2017.02.011_bib38","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/S0928-0987(02)00124-0","article-title":"Isosorbide-based aspirin prodrugs: II. Hydrolysis kinetics of isosorbide diaspirinate","volume":"16","author":"Gilmer","year":"2002","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejmech.2017.02.011_bib39","first-page":"183","article-title":"Paraoksonaza 1-co o niej obecnie wiadomo? Paraoxonase 1-what do we know today?","volume":"10","author":"Gajewski","year":"2015","journal-title":"Folia Cardiol."},{"key":"10.1016\/j.ejmech.2017.02.011_bib40","doi-asserted-by":"publisher","first-page":"523","DOI":"10.4103\/1947-2714.103310","article-title":"Antioxidant and anti-inflammatory role of paraoxonase 1: implication in arteriosclerosis diseases","volume":"4","author":"Litvinov","year":"2012","journal-title":"N.\u00a0Am. J. Med. Sci."},{"key":"10.1016\/j.ejmech.2017.02.011_bib41","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1021\/tx2004085","article-title":"Cytochromes P450 catalyze both steps of the major pathway of clopidogrel bioactivation, whereas paraoxonase catalyzes the formation of a minor thiol metabolite isomer","volume":"25","author":"Dansette","year":"2012","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.ejmech.2017.02.011_bib42","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s00210-003-0833-1","article-title":"Pharmacogenetics of paraoxonases: a brief review","volume":"369","author":"Draganov","year":"2004","journal-title":"Schmiedeb. Arch. Pharmacol."},{"key":"10.1016\/j.ejmech.2017.02.011_bib43","first-page":"355","article-title":"Paraoxonase has a major role in the hydrolysis of prulifloxacin (NM441), a prodrug of a new antibacterial agent","volume":"26","author":"Tougou","year":"1998","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejmech.2017.02.011_bib44","first-page":"395","article-title":"Esterase-like activity of human serum albumin toward prodrug esters of nicotinic acid","volume":"25","author":"Salvi","year":"1997","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejmech.2017.02.011_bib45","doi-asserted-by":"publisher","first-page":"5535","DOI":"10.1016\/j.bbagen.2013.03.015","article-title":"Molecular and practical aspects of the enzymatic properties of human serum albumin and of albumin-ligand complexes","volume":"1830","author":"Kragh-Hansen","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejmech.2017.02.011_bib46","doi-asserted-by":"publisher","first-page":"3023","DOI":"10.1002\/jps.22505","article-title":"Reversion of sulfenamide prodrugs in the presence of free thiol containing proteins","volume":"100","author":"Nti-Addae","year":"2011","journal-title":"J.\u00a0Pharm. Sci."},{"key":"10.1016\/j.ejmech.2017.02.011_bib47","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1006\/abbi.1996.0310","article-title":"Expression and characterization of human pancreatic preprocarboxypeptidase A1 and preprocarboxypeptidase A2","volume":"332","author":"Laethem","year":"1996","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.ejmech.2017.02.011_bib48","doi-asserted-by":"crossref","first-page":"7894","DOI":"10.1016\/S0021-9258(19)40899-5","article-title":"Human liver aldehyde dehydrogenase. Esterase activity","volume":"250","author":"Sidhu","year":"1975","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2017.02.011_bib49","doi-asserted-by":"crossref","first-page":"4221","DOI":"10.1016\/S0021-9258(18)95800-X","article-title":"Esterase activities of human carbonic anhydrases B and C","volume":"242","author":"Verpoorte","year":"1967","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2017.02.011_bib50","doi-asserted-by":"publisher","first-page":"517","DOI":"10.3109\/10611869509015922","article-title":"Synthesis and the stereoselective enzymatic hydrolysis of flurbiprofen-basic amino acid ethyl esters","volume":"2","author":"Tsunematsu","year":"1995","journal-title":"J.\u00a0Drug Target"},{"key":"10.1016\/j.ejmech.2017.02.011_bib51","first-page":"915","article-title":"Relationship between lipase and esterase","volume":"344","author":"Tsujita","year":"1990","journal-title":"Prog. Clin. Biol. Res."},{"key":"10.1016\/j.ejmech.2017.02.011_bib52","series-title":"Drug Metabolism, in: Goodman and Gilman's the Pharmacological Basis of Therapeutics","first-page":"71","author":"Gonzalez","year":"2006"},{"key":"10.1016\/j.ejmech.2017.02.011_bib53","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/cbdv.200790032","article-title":"The biochemistry of drug metabolism-an introduction: Part 2. Redox reactions and their enzymes","volume":"4","author":"Testa","year":"2007","journal-title":"Chem. Biodivers."},{"key":"10.1016\/j.ejmech.2017.02.011_bib54","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1002\/cbdv.200890214","article-title":"The biochemistry of drug metabolism\u2013an introduction: Part 6. Inter-individual factors affecting drug metabolism","volume":"5","author":"Kramer","year":"2008","journal-title":"Chem. Biodivers."},{"key":"10.1016\/j.ejmech.2017.02.011_bib55","doi-asserted-by":"publisher","first-page":"797","DOI":"10.2165\/00003088-200544080-00003","article-title":"Clinical pharmacokinetics of losartan","volume":"44","author":"Sica","year":"2005","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejmech.2017.02.011_bib56","first-page":"323","article-title":"Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics","volume":"11","author":"Neuvonen","year":"2010","journal-title":"Curr. Opin. Invest. Drugs"},{"key":"10.1016\/j.ejmech.2017.02.011_bib57","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1093\/eurheartj\/ehp296","article-title":"P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use","volume":"30","author":"Wallentin","year":"2009","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ejmech.2017.02.011_bib58","first-page":"25","article-title":"Pharmacokinetics of clopidogrel","volume":"25","author":"Caplain","year":"1999","journal-title":"Semin. Thromb. Hemos"},{"key":"10.1016\/j.ejmech.2017.02.011_bib59","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1124\/jpet.106.110577","article-title":"Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carboxylesterases, and clopidogrel is transesterificated in the presence of ethyl alcohol","volume":"319","author":"Tang","year":"2006","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejmech.2017.02.011_bib60","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1124\/dmd.109.029132","article-title":"Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite","volume":"38","author":"Kazui","year":"2010","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejmech.2017.02.011_bib61","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S0025-6196(11)60750-7","article-title":"Opioid metabolism","volume":"84","author":"Smith","year":"2009","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.ejmech.2017.02.011_bib62","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.2174\/092986708785909120","article-title":"Cytochrome P450 activated prodrugs: targeted drug delivery","volume":"15","author":"Huttunen","year":"2008","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2017.02.011_bib63","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.steroids.2007.07.009","article-title":"New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer","volume":"72","author":"Jordan","year":"2007","journal-title":"Steroids"},{"key":"10.1016\/j.ejmech.2017.02.011_bib64","doi-asserted-by":"publisher","first-page":"173","DOI":"10.2133\/dmpk.21.173","article-title":"Human carboxylesterase isozymes: catalytic properties and rational drug design","volume":"21","author":"Imai","year":"2006","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.ejmech.2017.02.011_bib65","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1146\/annurev.pharmtox.38.1.257","article-title":"The mammalian carboxylesterases: from molecules to functions","volume":"38","author":"Satoh","year":"1998","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.ejmech.2017.02.011_bib66","first-page":"11","article-title":"Acetylo- i butyrylocholinoesteraza - budowa, funkcje i ich inhibitory. Acetyl- and butyrylcholinesterase - structure, functions and their inhibitors","volume":"30","author":"Bukowska","year":"2007","journal-title":"Curr. Top. Biophys."},{"key":"10.1016\/j.ejmech.2017.02.011_bib67","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1016\/S0047-6374(01)00309-8","article-title":"Acetylcholinesterase in Alzheimer's disease","volume":"122","author":"Talesa","year":"2001","journal-title":"Mech. Ageing Dev."},{"key":"10.1016\/j.ejmech.2017.02.011_bib68","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1021\/jm990436t","article-title":"Selective plasma hydrolysis of glucocorticoid gamma-lactones and cyclic carbonates by the enzyme paraoxonase: an ideal plasma inactivation mechanism","volume":"43","author":"Biggadike","year":"2000","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2017.02.011_bib69","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1124\/dmd.105.004226","article-title":"Identification of esterases expressed in Caco-2 cells and effects of their hydrolyzing activity in predicting human intestinal absorption","volume":"33","author":"Imai","year":"2005","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejmech.2017.02.011_bib70","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.jconrel.2016.04.010","article-title":"Readily adaptable release kinetics of prodrugs using protease-dependent reversible PEGylation","volume":"230","author":"B\u00f6ttger","year":"2016","journal-title":"J.\u00a0Control. Rel"},{"key":"10.1016\/j.ejmech.2017.02.011_bib71","doi-asserted-by":"publisher","first-page":"461","DOI":"10.2174\/1389200033489253","article-title":"Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: challenges to the discovery scientist","volume":"4","author":"Beaumont","year":"2003","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.ejmech.2017.02.011_bib72","doi-asserted-by":"publisher","first-page":"14046","DOI":"10.1002\/anie.201407130","article-title":"Cyclic-disulfide-based prodrugs for cytosol-specific drug delivery","volume":"53","author":"Butora","year":"2014","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2017.02.011_bib73","doi-asserted-by":"publisher","first-page":"181","DOI":"10.3851\/IMP2012","article-title":"Medicinal chemistry of nucleoside phosphonate prodrugs for antiviral therapy","volume":"22","author":"Pertusati","year":"2012","journal-title":"Antivir. Chem. Chemother."},{"key":"10.1016\/j.ejmech.2017.02.011_bib74","first-page":"556","article-title":"Prodrug strategies for improved efficacy of nucleoside antiviral inhibitors","volume":"8","author":"Hurwitz","year":"2013","journal-title":"Curr. Opin."},{"key":"10.1016\/j.ejmech.2017.02.011_bib75","first-page":"33","article-title":"Advances in nucleotide antiviral development from scientific discovery to clinical applications: tenofovir disoproxyl fumarate for Hepatitis B","volume":"1","author":"Lou","year":"2013","journal-title":"J.\u00a0Clin. Transl. Hepatol."},{"key":"10.1016\/j.ejmech.2017.02.011_bib76","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/hiv.12401","article-title":"The role of tenofovir alafenamide in future HIV management","volume":"17","author":"Antela","year":"2016","journal-title":"HIV Med."},{"key":"10.1016\/j.ejmech.2017.02.011_bib77","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.antiviral.2015.11.009","article-title":"Tenofovir alafenamide: a novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus","volume":"125","author":"Ray","year":"2016","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2017.02.011_bib78","doi-asserted-by":"publisher","first-page":"2896","DOI":"10.1016\/j.bmc.2014.03.031","article-title":"N4-Acyl derivatives as lipophilic prodrugs of cidofovir and its 5-azacytosine analogue, (S)-HMPM-5-azaC: chemistry and antiviral activity","volume":"22","author":"Kre\u010dmerov\u00e1","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2017.02.011_bib79","doi-asserted-by":"publisher","first-page":"8079","DOI":"10.1021\/jm050641a","article-title":"cyclo-Sal-PMEA and cycloAmb-PMEA: potentially new phosphonate prodrugs based on the cyclo-Sal-Pronucleotide approach","volume":"48","author":"Meier","year":"2005","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2017.02.011_bib80","doi-asserted-by":"publisher","first-page":"4958","DOI":"10.1021\/jm960289o","article-title":"Synthesis, in\u00a0vitro antiviral evaluation, and stability studies of bis(S-aryl-2-thioethyl) ester derivatives of 9[2-(phosphonomethoxy)ethyl]adenine (PMEA) as potential PMEA prodrugs with improved oral bioavailability","volume":"39","author":"Benzaria","year":"1996","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2017.02.011_bib81","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/S0960-894X(01)00128-7","article-title":"Synthesis and evaluation of novel amidate prodrugs of PMEA and PMPA","volume":"11","author":"Ballatore","year":"2001","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2017.02.011_bib82","doi-asserted-by":"publisher","first-page":"5154","DOI":"10.1021\/ja031818y","article-title":"Design, synthesis, and characterization of a series of cytochrome P450 3A-activated prodrugs (HepDirect prodrugs) useful for targeting phosphor(on)ate-based drugs to the liver","volume":"126","author":"Erion","year":"2004","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2017.02.011_bib83","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3851\/IMP1797","article-title":"Nucleotide prodrugs for HCV therapy","volume":"22","author":"Sofia","year":"2011","journal-title":"Antivir. Chem. Chemother."},{"key":"10.1016\/j.ejmech.2017.02.011_bib84","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1021\/ml4001497","article-title":"Adenosine dioxolane nucleoside phosphoramidates as antiviral agents for human immunodeficiency and Hepatitis B viruses","volume":"4","author":"Bondada","year":"2013","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2017.02.011_bib85","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/nature17180","article-title":"Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys","volume":"531","author":"Warren","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2017.02.011_bib86","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.ejmech.2013.09.047","article-title":"Design, synthesis and biological evaluation of phosphoradiamidate prodrugs of antiviral and anticancer nucleosides","volume":"70","author":"McGuigan","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2017.02.011_bib87","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1007\/s11095-013-1228-8","article-title":"Transdermal delivery and cutaneous targeting of antivirals using a penetration enhancer and lysolipid prodrugs","volume":"31","author":"Diblikov\u00e1","year":"2014","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejmech.2017.02.011_bib88","doi-asserted-by":"publisher","first-page":"8716","DOI":"10.1038\/ncomms9716","article-title":"Lipophilic prodrugs of nucleoside triphosphates as biochemical probes and potential antivirals","volume":"6","author":"Gollnest","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2017.02.011_bib89","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1016\/j.bmc.2012.02.031","article-title":"Synthesis and antiviral activity of 6-deoxycyclopropavir, a new prodrug of cyclopropavir","volume":"20","author":"Li","year":"2012","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2017.02.011_bib90","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.ejmech.2013.10.001","article-title":"Novel water-soluble prodrugs of acyclovir cleavable by the dipeptidyl-peptidase IV (DPP IV\/CD26) enzyme","volume":"70","author":"Diez-Torrubia","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2017.02.011_bib91","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.ijpharm.2012.05.033","article-title":"Targeted lipid based drug conjugates: a novel strategy for drug delivery","volume":"434","author":"Vadlapudi","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejmech.2017.02.011_bib92","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1089\/jop.2013.0157","article-title":"Aqueous nanomicellar formulation for topical delivery of biotinylated lipid prodrug of acyclovir: formulation development and ocular biocompatibility","volume":"30","author":"Vadlapudi","year":"2014","journal-title":"J.\u00a0Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2017.02.011_bib93","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1007\/s11095-013-1059-7","article-title":"Novel biotinylated lipid prodrugs of acyclovir for the treatment of Herpetic Keratitis (HK): transporter recognition, tissue stability and antiviral activity","volume":"30","author":"Vadlapudi","year":"2013","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejmech.2017.02.011_bib94","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1089\/jop.2008.0040","article-title":"Vitreal pharmacokinetics of biotinylated ganciclovir: role of sodium-dependent multivitamin transporter expressed on retina","volume":"25","author":"Janoria","year":"2009","journal-title":"J.\u00a0Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2017.02.011_bib95","doi-asserted-by":"publisher","first-page":"3249","DOI":"10.1002\/jps.23140","article-title":"Transporter-targeted lipid prodrugs of cyclic cidofovir: a potential approach for the treatment of cytomegalovirus retinitis","volume":"101","author":"Gokulgandhi","year":"2012","journal-title":"J.\u00a0Phar. Sci."},{"key":"10.1016\/j.ejmech.2017.02.011_bib96","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1021\/mp3007067","article-title":"Cytomegalovirus protease targeted prodrug development","volume":"10","author":"Sabit","year":"2013","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejmech.2017.02.011_bib97","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jconrel.2015.04.016","article-title":"Strategies for ribavirin prodrugs and delivery systems for reducing the side-effects hemolysis and enhancing their therapeutic effect","volume":"209","author":"Guo","year":"2015","journal-title":"J.\u00a0Control. Release"},{"key":"10.1016\/j.ejmech.2017.02.011_bib98","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.antiviral.2013.04.014","article-title":"Synthesis and evaluation of new phosphorylated ribavirin prodrug","volume":"99","author":"Dong","year":"2013","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2017.02.011_bib99","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.antiviral.2013.11.008","article-title":"Chutes and ladders in hepatitis C nucleoside drug development","volume":"102","author":"Coats","year":"2014","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2017.02.011_bib100","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1128\/JVI.02841-13","article-title":"Activation of peripheral blood mononuclear cells by Dengue Virus infection depontentiates balapiravir","volume":"88","author":"Chen","year":"2014","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ejmech.2017.02.011_bib101","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.antiviral.2015.07.010","article-title":"The search for nucleoside\/nucleotide analog inhibitors of dengue virus","volume":"122","author":"Chen","year":"2015","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2017.02.011_bib102","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.bmcl.2014.11.071","article-title":"A\u00a0prodrug strategy for oral delivery of poorly soluble HCV NS5B thumb pocket 1 polymerase inhibitor using self-emulsifying drug delivery systems (SEDDS)","volume":"25","author":"Beaulieu","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2017.02.011_bib103","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.bmc.2013.11.007","article-title":"Optimization of potency and pharmacokinetics of tricyclic indole derived inhibitors of HCV NS5B polymerase. Identification of ester prodrugs with improved oral pharmacokinetics","volume":"22","author":"Venkatraman","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2017.02.011_bib104","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ejmech.2015.09.015","article-title":"Synthesis of dihydropyrimidine \u03b1,\u03b3-diketobutanoic acid derivatives targeting HIV integrase","volume":"104","author":"Sari","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2017.02.011_bib105","doi-asserted-by":"publisher","first-page":"12623","DOI":"10.3390\/molecules200712623","article-title":"Integrase inhibitor prodrugs: approaches to enhancing the anti-HIV of \u03b2-diketo acids","volume":"20","author":"Nair","year":"2015","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2017.02.011_bib106","first-page":"3314","article-title":"Strategies for enzyme\/prodrug cancer therapy","volume":"7","author":"Xu","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2017.02.011_bib107","first-page":"11","article-title":"Proleki w terapii nowotwor\u00f3w. Cz\u0119\u015b\u0107 II. Strategie ADEPT i V\/GDEPT. Prodrugs in cancer therapy. Part II. ADEPT and V\/GDEPT strategies","volume":"5","author":"Sta\u0144czak","year":"2010","journal-title":"Farm. Przegl. Nauk."},{"key":"10.1016\/j.ejmech.2017.02.011_bib108","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1517\/14712598.4.11.1777","article-title":"Antibody-directed enzyme prodrug therapy (ADEPT) for cancer","volume":"4","author":"Bagshawe","year":"2004","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.ejmech.2017.02.011_bib109","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1586\/14737140.6.10.1421","article-title":"Antibody-directed enzyme prodrug therapy (ADEPT) for cancer","volume":"6","author":"Bagshawe","year":"2006","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.ejmech.2017.02.011_bib110","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1002\/cmdc.200700159","article-title":"Prodrug strategies in anticancer chemotherapy","volume":"3","author":"Kratz","year":"2008","journal-title":"Chem. Med. Chem."},{"key":"10.1016\/j.ejmech.2017.02.011_bib111","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1016\/j.addr.2007.08.022","article-title":"Directed evolution for drug and nucleic acid delivery","volume":"59","author":"Hida","year":"2007","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejmech.2017.02.011_bib112","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/S0169-409X(97)00032-X","article-title":"Antibody-directed enzyme prodrug therapy (ADEPT): a review","volume":"26","author":"Niculescu-Duvaz","year":"1997","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejmech.2017.02.011_bib113","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S0169-409X(01)00206-X","article-title":"Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates","volume":"53","author":"Senter","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejmech.2017.02.011_bib114","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1096\/fasebj.4.2.2404820","article-title":"Activation of prodrugs by antibody-enzyme conjugates: a new approach to cancer therapy","volume":"4","author":"Senter","year":"1990","journal-title":"FASEB J."},{"key":"10.1016\/j.ejmech.2017.02.011_bib115","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1021\/jm00059a018","article-title":"Prodrugs of doxorubicin and melphalan and their activation by a monoclonal antibody-penicillin-G amidase conjugate","volume":"36","author":"Vrudhula","year":"1993","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2017.02.011_bib116","first-page":"2151","article-title":"Tumor-selective prodrug activation by fusion protein-mediated catalysis","volume":"54","author":"Bosslet","year":"1994","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2017.02.011_bib117","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1021\/jm00008a016","article-title":"Cephalosporin derivatives of doxorubicin and melphalan and their activation by monoclonal antibody-lactamase conjugates","volume":"38","author":"Vrudhala","year":"1995","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2017.02.011_bib118","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.1016\/S0040-4039(00)79741-3","article-title":"Cephalosporin nitrogen mustard carbamate prodrugs for \u201eADEPT\u201d","volume":"32","author":"Alexander","year":"1991","journal-title":"Tetrahedron Lett."},{"key":"10.1016\/j.ejmech.2017.02.011_bib119","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1093\/jnci\/88.3-4.153","article-title":"Antibody-enzyme conjugates for cancer therapy","volume":"88","author":"Melton","year":"1996","journal-title":"J.\u00a0Natl. Cancer Inst."},{"key":"10.1016\/j.ejmech.2017.02.011_bib120","first-page":"2719","article-title":"Intratumoral generation of 5-fluorouracil mediated by an antibody-cytosine deaminase conjugate in combination with 5-fluorocytosine","volume":"54","author":"Wallace","year":"1994","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2017.02.011_bib121","doi-asserted-by":"publisher","first-page":"4842","DOI":"10.1073\/pnas.85.13.4842","article-title":"Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate","volume":"85","author":"Senter","year":"1988","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2017.02.011_bib122","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1002\/(SICI)1097-0215(19981209)78:6<712::AID-IJC8>3.0.CO;2-D","article-title":"In\u00a0vitro cytotoxity following specific activation of amygdalin by \u03b2-glucosidase conjugated to a bladder cancer-associated monoclonal antibody","volume":"78","author":"Syrigos","year":"1998","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejmech.2017.02.011_bib123","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/1097-4652(2001)9999:9999<::AID-JCP1060>3.0.CO;2-H","article-title":"Gene directed enzyme\/prodrug therapy of cancer: historical appraisal and future prospectives","volume":"187","author":"Greco","year":"2001","journal-title":"J.\u00a0Cell. Physiol."},{"key":"10.1016\/j.ejmech.2017.02.011_bib124","series-title":"Prodrugs Design \u2013 a New Era","first-page":"210","article-title":"Gene directed enzyme prodrug therapy (GDEPT)","author":"Sirhan","year":"2014"},{"key":"10.1016\/j.ejmech.2017.02.011_bib125","doi-asserted-by":"publisher","first-page":"9625","DOI":"10.3390\/ijms16059625","article-title":"A\u00a0fusion protein of RGD4C and \u03b2-lactamase has a favorable targeting effect in its use in antibody directed enzyme prodrug therapy","volume":"16","author":"Wang","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2017.02.011_bib126","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1073\/pnas.93.2.799","article-title":"Toward antibody-directed \u201cabzyme\u201d prodrug therapy, ADAPT: carbamate prodrug activation by a catalytic antibody and it in\u00a0vitro application to human tumor cell killing","volume":"93","author":"Wentworth","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2017.02.011_bib127","doi-asserted-by":"publisher","first-page":"6509","DOI":"10.1158\/1078-0432.CCR-06-0769","article-title":"A\u00a0phase I study of single administration of antibody-directed enzyme prodrug therapy with the recombinant anti-carcinoembryonic antigen antibody-enzyme fusion protein MFECP1 and a bis-iodo phenol mustard prodrug","volume":"12","author":"Mayer","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2017.02.011_bib128","first-page":"8","article-title":"A\u00a0phase I\/II trial of antibody directed enzyme prodrug therapy (ADEPT) with MFECP1 and ZD2767P","volume":"91","author":"Mayer","year":"2004","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2017.02.011_bib129","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1002\/med.21333","article-title":"Targeted prodrug approaches for hormone refractory prostate cancer","volume":"35","author":"Aloysius","year":"2015","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2017.02.011_bib130","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1093\/protein\/gzs044","article-title":"Design and analysis of immune-evading enzymes for ADEPT therapy","volume":"25","author":"Osipovitch","year":"2012","journal-title":"Protein. Eng. Des. Sel."},{"key":"10.1016\/j.ejmech.2017.02.011_bib131","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S0169-409X(96)00449-8","article-title":"Gene-directed enzyme prodrug therapy (GDEPT): choice of prodrugs","volume":"22","author":"Springer","year":"1996","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejmech.2017.02.011_bib132","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/S0169-409X(97)00033-1","article-title":"Gene directed enzyme prodrug therapy for cancer","volume":"26","author":"Kerr","year":"1997","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejmech.2017.02.011_bib133","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1124\/pr.56.1.3","article-title":"Enzyme-catalyzed activation of anticancer prodrugs","volume":"56","author":"Rooseboom","year":"2004","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejmech.2017.02.011_bib134","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1208\/s12248-014-9675-7","article-title":"Gene-directed enzyme prodrug therapy","volume":"17","author":"Zhang","year":"2015","journal-title":"AAPS J."},{"key":"10.1016\/j.ejmech.2017.02.011_bib135","first-page":"13","article-title":"E.R.Nemtsova, R.I. Yakubovskaya, E.D. Sverdlov, Therapeutic properties of a vector carrying the HSV thymidine kinase and GM-CSF genes and delivered as a complex with a cationic copolymer","volume":"4","author":"Alekseenko","year":"2015","journal-title":"J.\u00a0Trans. Med."},{"key":"10.1016\/j.ejmech.2017.02.011_bib136","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/annonc\/mdw440","article-title":"Vectorized gene therapy of liver tumors: proof of concept of TG4023 (MVA-FCU1) in combination with flucytosine","volume":"28","author":"Husseini","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejmech.2017.02.011_bib137","first-page":"48","article-title":"Suicide gene therapy","volume":"1","author":"William","year":"2003","journal-title":"J.\u00a0Biomed. Biotechnol."},{"key":"10.1016\/j.ejmech.2017.02.011_bib138","series-title":"Medicinal Chemistry of Anticancer Drugs","author":"Avendano","year":"2008"},{"key":"10.1016\/j.ejmech.2017.02.011_bib139","doi-asserted-by":"publisher","first-page":"3054","DOI":"10.1073\/pnas.91.8.3054","article-title":"Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in\u00a0vivo","volume":"91","author":"Chen","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2017.02.011_bib140","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1073\/pnas.89.1.33","article-title":"Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system","volume":"89","author":"Mullen","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2017.02.011_bib141","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/sj.bjc.6603930","article-title":"In\u00a0vitro evaluation of cancer-specific NF-\u03baB-CEA enhancer\u2013promoter system for 5-fluorouracil prodrug gene therapy in colon cancer cell lines","volume":"97","author":"Guo","year":"2007","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2017.02.011_bib142","first-page":"773","article-title":"Intratumoral 5-fluorouracil produced by cytosine deaminase\/5-fluorocytosine gene therapy is effective for experimental human glioblastomas","volume":"62","author":"Miller","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2017.02.011_bib143","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0040611","article-title":"Evaluation of a gene-directed enzyme-prodrug therapy (GDEPT) in human pancreatic tumor cells and their use in\u00a0vivo models for pancreatic cancer","volume":"7","author":"Hlavaty","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ejmech.2017.02.011_bib144","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.2174\/1381612033454117","article-title":"Prodrugs in genetic chemoradiotherapy","volume":"9","author":"Patterson","year":"2003","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ejmech.2017.02.011_bib145","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.2174\/1381612023394566","article-title":"Cytochrome P450 gene-directed enzyme prodrug therapy (GDEPT) for cancer","volume":"8","author":"Chen","year":"2002","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ejmech.2017.02.011_bib146","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1002\/cam4.668","article-title":"Recombinant horseradish peroxidase variants for targeted cancer treatment","volume":"5","author":"Bonifert","year":"2016","journal-title":"Cancer Mde"},{"key":"10.1016\/j.ejmech.2017.02.011_bib147","article-title":"Combined enzyme\/prodrug treatment by genetically engineered AT-MSC exerts synergy and inhibits growth of MDA-MB-231 induced lung metastases","volume":"9","author":"Matuskova","year":"2015","journal-title":"J.\u00a0Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2017.02.011_bib148","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.biochi.2014.06.016","article-title":"Mesenchymal stem cells as cellular vehicles for prodrug gene therapy against tumors","volume":"105","author":"Amara","year":"2014","journal-title":"Biochimie"},{"key":"10.1016\/j.ejmech.2017.02.011_bib149","doi-asserted-by":"publisher","first-page":"794","DOI":"10.3109\/1061186X.2010.529909","article-title":"Lectin-directed enzyme activated prodrug therapy (LEAPT): synthesis and evaluation of rhamnose-capped prodrugs","volume":"18","author":"Garnier","year":"2010","journal-title":"J.\u00a0Drug Target"},{"key":"10.1016\/j.ejmech.2017.02.011_bib150","doi-asserted-by":"publisher","first-page":"14527","DOI":"10.1073\/pnas.0303574101","article-title":"LEAPT: lectin-directed enzyme-activated prodrug therapy","volume":"101","author":"Robinson","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2017.02.011_bib151","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/35092620","article-title":"Immune recognition: a new receptor for \u03b2-glucans","volume":"413","author":"Brown","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2017.02.011_bib152","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1126\/science.1069540","article-title":"Mannose receptor-mediated regulation of serum glycoprotein homeostasis","volume":"295","author":"Lee","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2017.02.011_bib153","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/0268-960X(88)90009-4","article-title":"Gaucher disease","volume":"2","author":"Beutler","year":"1988","journal-title":"Blood Rev."},{"key":"10.1016\/j.ejmech.2017.02.011_bib154","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1002\/jmv.10245","article-title":"Long-term survival and virus production in human primary macrophages infected by human immunodeficiency virus","volume":"68","author":"Aquaro","year":"2002","journal-title":"J.\u00a0Med. Virol."},{"key":"10.1016\/j.ejmech.2017.02.011_bib155","doi-asserted-by":"publisher","first-page":"12023","DOI":"10.1038\/srep12023","article-title":"Programmed hydrolysis in designing paclitaxel prodrug for nanocarrier assembly","volume":"5","author":"Fu","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2017.02.011_bib156","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1097\/PPO.0000000000000131","article-title":"Mechanisms of drugs resistance related to the microenvironment od solid tumors and possible strategies to inhibit them","volume":"21","author":"Tan","year":"2015","journal-title":"Cancer J."},{"key":"10.1016\/j.ejmech.2017.02.011_bib157","first-page":"393","article-title":"Targeting hypoxia in cancer therapy","volume":"11","author":"Wilson","year":"2011","journal-title":"Nature Rev."},{"key":"10.1016\/j.ejmech.2017.02.011_bib158","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1158\/1078-0432.CCR-11-1980","article-title":"Selective tumor hypoxia targeting by huypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer","volume":"18","author":"Sun","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2017.02.011_bib159","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.1002\/ijc.28595","article-title":"Activity of the hypoxia-activated pro-drug TH-302 in hypoxic and perivascular regions of solid tumors and its potential to enhance therapeutic effects of vhemotherapy","volume":"134","author":"Saggar","year":"2014","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejmech.2017.02.011_bib160","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1021\/jm401853a","article-title":"Application of ProTide Technology to gemcitabine: a successful approach to overcome the key cancer resistance mechanisms leads to a new agent (NUC-1031) in clinical development","volume":"57","author":"Slusarczyk","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2017.02.011_bib161","doi-asserted-by":"publisher","first-page":"6242","DOI":"10.1016\/j.bmcl.2012.08.008","article-title":"Design of a hypoxia-activated prodrug inhibitor of O6-alkylguanine-DNA alkyltransferase","volume":"22","author":"Zhu","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2017.02.011_bib162","doi-asserted-by":"publisher","first-page":"823","DOI":"10.4155\/tde.12.61","article-title":"ROS-activated anticancer prodrugs: a new strategy for tumor-specific damage","volume":"3","author":"Peng","year":"2012","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.ejmech.2017.02.011_bib163","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jconrel.2015.11.030","article-title":"Activation of multiple chemotherapeutic prodrugs by the natural enzymolome of tumor-localised probiotic bacteria","volume":"222","author":"Lehouritis","year":"2016","journal-title":"J.\u00a0Control. Rel"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523417300764?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523417300764?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T05:19:57Z","timestamp":1749964797000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523417300764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":163,"alternative-id":["S0223523417300764"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2017.02.011","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Strategies in the designing of prodrugs, taking into account the antiviral and anticancer compounds","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2017.02.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}